Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G/A

ACHILLION PHARMACEUTICALS INC Form SC 13G/A February 14, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

Information To Be Included In Statements Filed Pursuant To § 240.13d-1(b), (c), and (d) and Amendments Thereto Filed Pursuant To § 240.13d-2

Under the Securities Exchange Act of 1934

Amendment No. 1*

Achillion Pharmaceuticals, Inc. (Name of Issuer)

Common Stock, \$0.001 par value per share (Title of Class of Securities)

00448Q201 (CUSIP Number)

December 31, 2011 (Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

0	Rule 13d-1(b)
X	Rule 13d-1(c)
0	Rule 13d-1(d)

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 2 of 7 Pages

- NAMES OF REPORTING PERSONS Quaker BioVentures II, L.P. Quaker BioVentures Capital II, L.P. Quaker BioVentures Capital II, LLC
- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) o

SCHEDULE 13G

(b) o

*

- 3 SEC USE ONLY
- 4 CITIZENSHIP OR PLACE OF ORGANIZATION Quaker BioVentures II, L.P. – Delaware Quaker BioVentures Capital II, L.P. – Delaware Quaker BioVentures Capital II, LLC – Delaware

	5	SOLE VOTING POWER*
		Quaker BioVentures II, L.P. – 0
		Quaker BioVentures Capital II, L.P. – 0
		Quaker BioVentures Capital II, LLC – 0
NUMBER OF	6	SHARED VOTING POWER
SHARES		Quaker BioVentures II, L.P. – 2,863,253
BENEFICIALLY		Quaker BioVentures Capital II, L.P. – 2,863,253
OWNED BY		Quaker BioVentures Capital II, LLC – 2,863,253
EACH	7	SOLE DISPOSITIVE POWER
REPORTING		Quaker BioVentures II, L.P. – 0
PERSON		Quaker BioVentures Capital II, L.P. – 0
WITH		Quaker BioVentures Capital II, LLC – 0
	8	SHARED DISPOSITIVE POWER
		Quaker BioVentures II, L.P. – 2,863,253
		Quaker BioVentures Capital II, L.P. – 2,863,253
		Quaker BioVentures Capital II, LLC – 2,863,253

 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON Quaker BioVentures II, L.P. – 2,863,253 Quaker BioVentures Capital II, L.P. – 2,863,253 Quaker BioVentures Capital II, LLC – 2,863,253

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) o

- PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9** Quaker BioVentures II, L.P. – 4.1% Quaker BioVentures Capital II, L.P. – 4.1% Quaker BioVentures Capital II, LLC – 4.1%
 TYPE OF REPORTING REPSON (SEE INSTRUCTIONS)
- 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) Quaker BioVentures II, L.P. – PN Quaker BioVentures Capital II, L.P. – PN Quaker BioVentures Capital II, LLC – OO

All share numbers and ownership percentages reported herein are as of December 31, 2011.

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G/A

** All ownership percentages reported herein are based on 69,743,721 outstanding shares of the Issuer's common stock as of November 1, 2011.

CUSIP No. 00448Q201		SCHEDULE 13G	Page 3 of 7 Pages
Item 1(a)	Name of Issuer:		
	Achillion Pharmaceu	ticals, Inc.	
Item 1(b)	Address of Issuer's Principal Executive Offices:		
	300 George Street, N	ew Haven, CT 06511	
Item 2(a)	Name of Person Filin	ıg:	
	Quaker BioVentures		
	Quaker BioVentures Quaker BioVentures		
Item 2(b)	Address of Principal	Business Office or, if none, Res	idence:
	•	incipal business office of each o Cira Centre, Philadelphia, PA 19	· · ·
Item 2(c)	Citizenship:		
	Quaker BioVentures Quaker BioVentures	II, L.P. – Delaware Capital II, L.P. – Delaware	
	Quaker BioVentures	Capital II, LLC – Delaware	
Item 2(d)	Title of Class of Secu	irities:	
	Common Stock, \$0.0	01 par value per share	
Item 2(e)	CUSIP Number:		
	00448Q201		
Item 3	Not applicable.		

SCHEDULE 13G

Page 4 of 7 Pages

Item 4 Ownership.***

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

Quaker BioVentures II, L.P. – 2,863,253 Quaker BioVentures Capital II, L.P. – 2,863,253 Quaker BioVentures Capital II, LLC – 2,863,253

(b) Percent of class:

Quaker BioVentures II, L.P. – 4.1% Quaker BioVentures Capital II, L.P. – 4.1% Quaker BioVentures Capital II, LLC – 4.1%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

Quaker BioVentures II, L.P. – 0 Quaker BioVentures Capital II, L.P. – 0 Quaker BioVentures Capital II, LLC – 0

(ii) Shared power to vote or to direct the vote

Quaker BioVentures II, L.P. – 2,863,253 Quaker BioVentures Capital II, L.P. – 2,863,253 Quaker BioVentures Capital II, LLC – 2,863,253

(iii) Sole power to dispose or to direct the disposition of

Quaker BioVentures II, L.P. -0Quaker BioVentures Capital II, L.P. -0Quaker BioVentures Capital II, LLC -0

(iv) Shared power to dispose or to direct the disposition of

Quaker BioVentures II, L.P. – 2,863,253 Quaker BioVentures Capital II, L.P. – 2,863,253 Quaker BioVentures Capital II, LLC – 2,863,253

Quaker BioVentures Capital II, L.P. is the general partner of Quaker BioVentures II, L.P. Quaker BioVentures Capital II, LLC is the general partner of Quaker BioVentures Capital II, L.P.

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G/A				
Item 5	Ownership of Five Percent or Less of a Class.			
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following box. x			
Item 6	Ownership of More than Five Percent on Behalf of Another Person.			
	Not applicable.			
Item 7	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.			
	Not applicable.			

Edgar Filing: ACHILLION PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 00448Q201		SCHEDULE 13G	Page 5 of 7 Pages
Item 8	Identification and Classification of Members of the Group.		
	with respect to the iss	Persons may be deemed to be a uer or securities of the issuer for Securities Exchange Act of 1934	the purpose of Section
Item 9	Notice of Dissolution	of Group.	
	Not applicable.		
Item 10	Certification.		
	securities referred to a of or with the effect o securities and were no	ertify that, to the best of my know above were not acquired and are f changing or influencing the co of acquired and are not held in co associon having that purpose or e	not held for the purpose ntrol of the issuer of the onnection with or as a

SCHEDULE 13G

Page 6 of 7 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2012

QUAKER BIOVENTURES II, L.P.

By: Quaker BioVentures Capital II, L.P., its general partner

By: Quaker BioVentures Capital II, LLC, its general partner

/s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President

QUAKER BIOVENTURES CAPITAL II, L.P.

By: Quaker BioVentures Capital II, LLC, its general partner

/s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President

QUAKER BIOVENTURES CAPITAL II, LLC

/s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President

SCHEDULE 13G

Page 7 of 7 Pages

JOINT FILING AGREEMENT

Exhibit 1

Joint Filing Agreement, dated as of February 14, 2012, is by and among Quaker BioVentures II, L.P., Quaker BioVentures Capital II, L.P. and Quaker BioVentures Capital II, LLC (the "Quaker Filers").

Each of the Quaker Filers may be required to file with the United States Securities and Exchange Commission a statement on Schedule 13G with respect to shares of Common Stock, par value \$0.001 per share, of Achillion Therapeutics, Inc. beneficially owned by it from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the Quaker Filers hereby agree to be responsible for the timely filing of the Schedule 13G and any amendments thereto on behalf of the Quaker Filers, and for the completeness and accuracy of the information concerning itself contained therein. Each of the Quaker Filers hereby further agree to file this Joint Filing Agreement as an exhibit to the statement and each such amendment, as required by such rule.

This Joint Filing Agreement may be terminated by any of the Quaker Filers upon one week's prior written notice or such lesser period of notice as the Quaker Filers may mutually agree.

Executed and delivered as of the date first above written.

QUAKER BIOVENTURES II, L.P.

By: Quaker BioVentures Capital II, L.P., its general partner

By: Quaker BioVentures Capital II, LLC, its general partner

/s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President

QUAKER BIOVENTURES CAPITAL II, L.P.

By: Quaker BioVentures Capital II, LLC, its general partner

/s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President

QUAKER BIOVENTURES CAPITAL II, LLC

/s/ Richard S. Kollender Name: Richard S. Kollender Title: Vice President